Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Other hematologic neoplasm 1Lymphoid 1CNS 1

Conditions

Sarcoma 1Neuroblastoma 1Lymphoma 1Leukemia 1Central Nervous System Neoplasms 1

Interventions

Temozolomide 58Radiotherapy 50Carmustine 23Carboplatin 18Filgrastim 17Chemotherapy, Adjuvant 17Irinotecan 12Surgical Procedures, Operative 11Peripheral Blood Stem Cell Transplantation 11O(6)-benzylguanine 10Magnetic Resonance Spectroscopy 10Drug Therapy 10Etoposide 9sargramostim 8Thiotepa 8Thalidomide 8Cyclophosphamide 8Bevacizumab 8Procarbazine 7Gene Expression Profiling 7Erlotinib Hydrochloride 7Radiation 6Everolimus 6Cisplatin 6motexafin gadolinium 5aldesleukin 5Topotecan 5Imatinib Mesylate 5Celecoxib 5Busulfan 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Central Nervous System Neoplasms × Fenofibrate × Sarcoma × Clear all
NCT00357500 2014-10-01

Etoposide, Cyclophosphamide, Thalidomide, Celecoxib, and Fenofibrate in Relapsed or Progressive Cancer

Dana-Farber Cancer Institute

Phase 2 Completed
101 enrolled 10 charts
CNSLymphoidOther hematologic neoplasmSarcoma

Leukemia, Lymphoma, Neuroblastoma, Sarcoma, Central Nervous System Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡